• Vaccine Name: Marburg Virus Vaccine Ad26.Filo, MVA-BN-Filo
• Target Pathogen: Marburg Virus
• Target Disease: Hemorrhagic fever
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Antigen: Ebola virus Mayinga Glycoprotein, Sudan Virus Gulu Glycoprotein, Marburg Virus Angola Glycoprotein (Tiemessen et al., 2022)
• GP from Zaire ebolavirus gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• GP Sudan ebolavirus gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• GP from Musoke Marburgvirus gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• NP from Tai Forest Ebolavirus gene engineering:
  • Type: Recombinant vector construction
  • Description:
  • Detailed Gene Information: Click Here.
• Preparation: This vaccine includes two doses with two different vaccine formulae - Ad26.Filo and MVA-BN-Filo. For Ad26.Filo , ..... Replication-incompetent, E1/E3-deleted recombinant adenoviral vectors based on Ad26 were engineered using the AdVac® system with the humanized GP DNA sequences for EBOV Mayinga (Ad26.ZEBOV), SUDV Gulu (Ad26.SUDV), and MARV Angola (Ad26.MARVA). The combination of these three Ad26 vectors in a 1:1:1 ratio will be further referred to as Ad26.Filo; MVA-BN-Filo is a recombinant, modified vaccinia Ankara-vectored vaccine, non-replicating in human cells, encoding the EBOV Mayinga, SUDV Gulu, and MARV Musoke GPs as well as the nucleoprotein of the Tai Forest virus. Adenovirus vaccines were given at 1.2 × 10^11 viral particles (vp; 4 × 10^10 vp/vector) and the MVA-BN-Filo vector at a dose of 5 × 10*8 infectious units (infU). MVA-BN-Filo is composed of the Tai Forest Virus. (Tiemessen et al., 2022).
• Immunization Route: Intramuscular injection (i.m.)
• Description: Two-dose regimen, consisting of Ad26.Filo followed by MVA-BN-Filo with an 8-week interval (Tiemessen et al., 2022)

Macaque Response

• Vaccination Protocol: For that purpose, 16 cynomolgus macaques were assigned to four groups: one control group (n = 2) and three groups each receiving a different vaccine regimen (Table 2). The negative control group received an Ad26 empty vector followed by Tris buffer as dose 2. The three groups immunized with vaccine regimens received either Ad26.Filo, Ad35.Filo (n = 4); Ad26.Filo, MVA-BN-Filo (n = 5); or MVA-BN-Filo, Ad26.Filo regimen (n = 5). Adenovirus vaccines were given at 1.2 × 10^11 vp (4 × 10^10 vp/vector) and the MVA-BN-Filo vector at a dose of 5 × 108 infU. (Tiemessen et al., 2022)
• Immune Response: The MARV GP–specific antibody levels induced by the three different heterologous vaccine regimens were very similar 3 weeks post-dose 2 (study week 11). However, the MARV GP–specific antibody levels induced post-dose 1, at study weeks 4 and 8, were lower post-MVA compared to post-Ad26. Additionally, MARV-specific neutralizing antibodies could be detected in all immunized animals except for two animals in the MVA-BN-Filo, Ad26.Filo group.
• Side Effects: ne animal of the Ad26.Filo, MVA-BN-Filo regimen group (NHP 33841), that experienced transient severe clinical symptoms from day 8 until day 12 after infection, showed the lowest MARV GP–specific antibody concentration in serum at weeks 10 and 11 from the 5 animals in that group (2.45 and 2.26 EU/mL [log10]). MARV GP–specific binding antibody concentrations are good predictors for survival outcome after challenge, even when analyzed across various vaccination regimens. (Tiemessen et al., 2022)
• Challenge Protocol: Four weeks after dose 2, the animals were challenged i.m. with 1000 pfu MARV Angola. (Tiemessen et al., 2022)
• Efficacy: 21 days post-dose 2, 100% of participants on the active regimen responded to vaccination and exhibited binding antibodies against EBOV, SUDV, and MARV GPs. (Tiemessen et al., 2022)